Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
826
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Benefits of rIX-FP prophylaxis in patients with Haemophilia B: real-world evidence from a Spanish reference centre

Olga Benítez-Hidalgoa Servei d’Hematologia, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, Barcelona, Spain;b Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2883-9049View further author information
ORCID Icon,
Marc Bosch Schipsa Servei d’Hematologia, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, Barcelona, Spain;b Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, SpainView further author information
,
Juan Carlos Juárez Giménezc Pharmacy Department, Vall d’Hebron University Hospital, Barcelona, SpainView further author information
&
Mercedes Gironellaa Servei d’Hematologia, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Vall d’Hebron Hospital Universitari, Barcelona, Spain;b Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, SpainView further author information
Article: 2242656 | Received 10 Feb 2023, Accepted 26 Jul 2023, Published online: 07 Sep 2023

References

  • Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia. 2008;14(Suppl. 3):10–18.
  • Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev. 2013;34(7):289–294. quiz 95.
  • Franchini M. Current management of hemophilia B: recommendations, complications and emerging issues. Expert Rev Hematol. 2014;7(5):573–581. doi:10.1586/17474086.2014.947955.
  • Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study). J Thromb Haemost. 2011;9(4):700–710. doi:10.1111/j.1538-7836.2011.04214.x.
  • Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659.
  • Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–553. doi:10.3324/haematol.2019.232132.
  • Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J Blood Med. 2013;4:49–56.
  • Mancuso ME, Lubetsky A, Pan-Petesch B, et al. Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B. J Thromb Haemost. 2020;18(5):1065–1074. doi:10.1111/jth.14778.
  • Lyseng-Williamson KA. Coagulation factor IX (recombinant), albumin fusion protein (Albutrepenonacog Alfa; Idelvion(®)): a review of its use in haemophilia B. Drugs. 2017;77(1):97–106. doi:10.1007/s40265-016-0679-8.
  • Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405–2411. doi:10.1182/blood-2012-05-429688.
  • Álvarez Román MT, Benítez O, Canaro MI, et al. Expert opinion paper on the treatment of hemophilia B with Albutrepenonacog Alfa. Expert Opin Biol Ther. 2021;21(9):1165–1171. doi:10.1080/14712598.2021.1932811.
  • Escobar M, Mancuso ME, Hermans C, et al. Idelvion: a comprehensive review of clinical trial and real-world data. J Clin Med. 2022;11(4):1. doi:10.3390/jcm6040039.
  • Kenet G, Chambost H, Male C, et al. Long-term safety and efficacy of recombinant coagulation factor IX albumin fusion protein (rIX-FP) in previously treated pediatric patients with hemophilia B: results from a phase 3b extension study. Thromb Haemost. 2020;120(4):599–606. doi:10.1055/s-0040-1705116.
  • Hermans C, Marino R, Lambert C, et al. Real-world utilisation and bleed rates in patients with haemophilia B who switched to recombinant factor IX fusion protein (rIX-FP): a retrospective international analysis. Adv Ther. 2020;37(6):2988–2998. doi:10.1007/s12325-020-01300-6.
  • Oldenburg J, Yan S, Maro G, et al. Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy. Curr Med Res Opin. 2020;36(1):9–15. doi:10.1080/03007995.2019.1662675.
  • Rodríguez López M, Megías Vericat JE, Albo López C, et al. Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (Albutrepenonacog Alfa, rFIX-FP) in Spain. BMJ Case Rep. 2020;13(10):e234142. doi:10.1136/bcr-2019-234142.
  • von Mackensen S, Shah J, Seifert W, et al. Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP. Haemophilia. 2019;25(1):45–53. doi:10.1111/hae.13624.
  • Mancuso ME, Oldenburg J, Boggio L, et al. High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: evidence from clinical trials and real-world practice. Haemophilia. 2020;26(4):637–642. doi:10.1111/hae.14018.
  • Gill JC, Roberts J, Li Y, et al. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019;25(3):e219–e222.
  • Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol. 2018;11(8):673–683. doi:10.1080/17474086.2018.1489719.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.